Medtronic Published (ADAPT) Study Results of MiniMed 780G System for Type 1 Diabetes in The Lancet Diabetes & Endocrinology
Shots:
- The (ADAPT) study evaluating MiniMed 780G system vs SoC (MDI + CGM) in patients with T1D
- The study showed an improvement in glycemic targets who transit to MiniMed 780G system with a sustained HbA1C reduction (1.4%) @6mos. & 27.6% absolute increase in time in range over SoC without increased in time in hypoglycemia, 27.8% use MiniMed 780G system achieved an HbA1c ≤7% while none of the patients who continued taking MDI + isCGM got the intended outcome
- Patients experienced an increase in treatment satisfaction, reduction in fear of hypoglycemia & had improvement across all glycemic metrics who transitioned to MiniMed 780G system. The system is available in ~60 countries globally and is currently under the US FDA’s review
Ref: PR Newswire | Image: Medtronic
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
